Testosterone replacement therapy and cardiovascular disease
- PMID: 34999717
- DOI: 10.1038/s41443-021-00516-6
Testosterone replacement therapy and cardiovascular disease
Abstract
The use of testosterone therapy has a complex history of apprehension and questions regarding its safety. Despite an eventual consensus that testosterone therapy was safe and effective, several studies relating to cardiovascular risks emerged in the last decade, rekindling skepticism regarding the safety of testosterone therapy. Given the utility of testosterone therapy in treating the symptoms of hypogonadism, it remains crucial to closely examine the safety of testosterone therapy. The present article synthesizes the current evidence regarding cardiovascular risks that may be associated with testosterone therapy, the potential mechanisms regarding testosterone's efficacy, and future directions in evaluating the safety of its use.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Comment in
-
Commentary on: Testosterone replacement therapy and cardiovascular disease.Int J Impot Res. 2022 Nov;34(7):691-692. doi: 10.1038/s41443-022-00625-w. Epub 2022 Oct 5. Int J Impot Res. 2022. PMID: 36198810 No abstract available.
Similar articles
-
Hypogonadism management and cardiovascular health.Postgrad Med. 2020 Dec;132(sup4):35-41. doi: 10.1080/00325481.2020.1805917. Epub 2020 Oct 19. Postgrad Med. 2020. PMID: 32799602 Review.
-
Testosterone replacement therapy and cardiovascular events.Turk Kardiyol Dern Ars. 2017 Oct;45(7):664-672. doi: 10.5543/tkda.2017.00531. Turk Kardiyol Dern Ars. 2017. PMID: 28990951 Review.
-
Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations.Med J Aust. 2016 Sep 5;205(5):228-31. doi: 10.5694/mja16.00448. Med J Aust. 2016. PMID: 27581270
-
Cardiovascular disease and testosterone therapy in male hypogonadism.Ann N Y Acad Sci. 2024 Oct;1540(1):121-132. doi: 10.1111/nyas.15211. Epub 2024 Sep 7. Ann N Y Acad Sci. 2024. PMID: 39243393 Review.
-
Re: Cardiovascular Safety of Testosterone-Replacement Therapy.Eur Urol. 2024 Feb;85(2):182. doi: 10.1016/j.eururo.2023.09.029. Epub 2023 Oct 19. Eur Urol. 2024. PMID: 37865548 No abstract available.
Cited by
-
Aromatase Inhibitors May Increase the Risk of Cardiometabolic Complications in Adolescent Boys.Pediatr Cardiol. 2024 Feb;45(2):228-239. doi: 10.1007/s00246-023-03260-4. Epub 2023 Aug 6. Pediatr Cardiol. 2024. PMID: 37544952 Review.
-
Testosterone promotes the migration, invasion and EMT process of papillary thyroid carcinoma by up-regulating Tnnt1.J Endocrinol Invest. 2024 Jan;47(1):149-166. doi: 10.1007/s40618-023-02132-1. Epub 2023 Jul 21. J Endocrinol Invest. 2024. PMID: 37477865 Free PMC article.
References
-
- Tsametis CP, Isidori AM. Testosterone replacement therapy: for whom, when and how?. Metabolism. 2018;86:69–78. https://doi.org/10.1016/j.metabol.2018.03.007 . - DOI - PubMed
-
- Smith JB, Rosen J, Colbert A. Low serum testosterone in outpatient psychiatry clinics: addressing challenges to the screening and treatment of hypogonadism. Sex Med Rev. 2018;6:69–76. https://doi.org/10.1016/j.sxmr.2017.08.007 . - DOI - PubMed
-
- Dohle G, Arver S, Bettocchi C, Jones T, Kliesch S, Punab M. Guidelines on male hypogonadism. Eur Assoc Urol. 2015. https://doi.org/10.1007/978-1-60761-193-6 . - DOI
-
- Huggins C, Hodges CV. Studies on prostatic cancer i. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;22:232–40. https://doi.org/10.3322/canjclin.22.4.232 . - DOI
-
- Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170–83. https://doi.org/10.1093/jnci/djm323 . - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
